What Precigen, Inc. does.

We are a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients. We are leveraging our proprietary technology platforms to develop product candidates designed to target urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases.

We believe that our array of technology platforms uniquely positions us among other biotechnology companies to advance precision medicine. Precision medicine is the practice of therapeutic product development that takes into account specific genetic variations within populations impacted by a disease to design targeted therapies to improve outcomes for a disease or patient population. Our proprietary and complementary technology platforms provide a strong foundation to realize the core promise of precision medicine by supporting our efforts to construct powerful gene programs to drive efficacy, deliver these programs through viral, non-viral, and microbe-based approaches to drive lower costs, and control gene expression to drive safety. Our therapeutic platforms, including AdenoVerse immunotherapy, and UltraCAR-T, are designed to allow us to precisely control the level and physiological location of gene expression and modify biological molecules to control the function and output of living cells to treat underlying disease conditions. We have developed a proprietary electroporation device, UltraPorator, designed to further streamline and ensure the rapid and cost-effective manufacturing of UltraCAR-T therapies.

Revenue and profit, by fiscal year.

More on PGEN.

• Precigen, Inc. summary
• Precigen, Inc. financial statements
• Precigen, Inc. key metrics
• Precigen, Inc. health scores and style box
• Precigen, Inc. earnings
• Precigen, Inc. dividends
• Precigen, Inc. valuation
• Precigen, Inc. ownership and insiders
• Precigen, Inc. peers

Figures from Precigen, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.